logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Bempedoic Acid

Bempedoic Acid is the latest addition to our portfolio

In our portfolio since: 2020

Trademark: NILEMDO/NUSTENDI1

Indication:

Bempedoic acid2 inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.3 Bempedoic acid/ the fixed combination with ezetimibe is approved for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia in Europe.

▼​ This medicinal product is subject to additional monitoring. ​

References

1For legal reasons detailed information about prescription medicine may only be given to healthcare professionals.

2 Bempedoic acid / the combination of bempedoic acid with ezetimibe was approved by the EMA in April 2020 with a first market launch in late 2020.

3European Medicines Agency. NILEMDO® Summary of Product Characteristics. March 2020. Nilemdo, INN-bempedoic acid (europa.eu)

4European Medicines Agency. NUSTENDI® Summary of Product Characteristics. March 2020.  Nustendi, INN-bempedoic acid/ezetimibe (europa.eu)